346 related articles for article (PubMed ID: 28473401)
1. Ranolazine in Symptomatic Diabetic Patients Without Obstructive Coronary Artery Disease: Impact on Microvascular and Diastolic Function.
Shah NR; Cheezum MK; Veeranna V; Horgan SJ; Taqueti VR; Murthy VL; Foster C; Hainer J; Daniels KM; Rivero J; Shah AM; Stone PH; Morrow DA; Steigner ML; Dorbala S; Blankstein R; Di Carli MF
J Am Heart Assoc; 2017 May; 6(5):. PubMed ID: 28473401
[TBL] [Abstract][Full Text] [Related]
2. Late sodium channel blockade improves angina and myocardial perfusion in patients with severe coronary microvascular dysfunction: Women's Ischemia Syndrome Evaluation-Coronary Vascular Dysfunction ancillary study.
Rambarat CA; Elgendy IY; Handberg EM; Bairey Merz CN; Wei J; Minissian MB; Nelson MD; Thomson LEJ; Berman DS; Shaw LJ; Cook-Wiens G; Pepine CJ
Int J Cardiol; 2019 Feb; 276():8-13. PubMed ID: 30293664
[TBL] [Abstract][Full Text] [Related]
3. Ranolazine improves angina in women with evidence of myocardial ischemia but no obstructive coronary artery disease.
Mehta PK; Goykhman P; Thomson LE; Shufelt C; Wei J; Yang Y; Gill E; Minissian M; Shaw LJ; Slomka PJ; Slivka M; Berman DS; Bairey Merz CN
JACC Cardiovasc Imaging; 2011 May; 4(5):514-22. PubMed ID: 21565740
[TBL] [Abstract][Full Text] [Related]
4. Microvascular Assessment of Ranolazine in Non-Obstructive Atherosclerosis: The MARINA Randomized, Double-Blinded, Controlled Pilot Trial.
Koh JS; Hung OY; Eshtehardi P; Kumar A; Rabah R; Raad M; Kumar S; Chaudhry S; Gupta S; Hosseini H; Brilakis E; Corban M; Sabbak N; Burnett GM; Liu C; Mehta PK; Quyyumi AA; Samady H
Circ Cardiovasc Interv; 2020 Dec; 13(12):e008204. PubMed ID: 33272036
[TBL] [Abstract][Full Text] [Related]
5. Effects of ranolazine on noninvasive coronary flow reserve in patients with myocardial ischemia but without obstructive coronary artery disease.
Tagliamonte E; Rigo F; Cirillo T; Astarita C; Quaranta G; Marinelli U; Caruso A; Romano C; Capuano N
Echocardiography; 2015 Mar; 32(3):516-21. PubMed ID: 25041234
[TBL] [Abstract][Full Text] [Related]
6. Ranolazine reduces repolarization heterogeneity in symptomatic patients with diabetes and non-flow-limiting coronary artery stenosis.
Evaristo E; Stocco FG; Shah NR; Cheezum MK; Hainer J; Foster C; Nearing BD; Di Carli M; Verrier RL
Ann Noninvasive Electrocardiol; 2018 Jan; 23(1):. PubMed ID: 28653394
[TBL] [Abstract][Full Text] [Related]
7. Myocardial tissue deformation is reduced in subjects with coronary microvascular dysfunction but not rescued by treatment with ranolazine.
Nelson MD; Sharif B; Shaw JL; Cook-Wiens G; Wei J; Shufelt C; Mehta PK; Thomson LEJ; Berman DS; Thompson RB; Handberg EM; Pepine CJ; Li D; Bairey Merz CN
Clin Cardiol; 2017 May; 40(5):300-306. PubMed ID: 28004395
[TBL] [Abstract][Full Text] [Related]
8. A study of the effects of ranolazine using automated quantitative analysis of serial myocardial perfusion images.
Venkataraman R; Belardinelli L; Blackburn B; Heo J; Iskandrian AE
JACC Cardiovasc Imaging; 2009 Nov; 2(11):1301-9. PubMed ID: 19909934
[TBL] [Abstract][Full Text] [Related]
9. A randomized, placebo-controlled trial of late Na current inhibition (ranolazine) in coronary microvascular dysfunction (CMD): impact on angina and myocardial perfusion reserve.
Bairey Merz CN; Handberg EM; Shufelt CL; Mehta PK; Minissian MB; Wei J; Thomson LE; Berman DS; Shaw LJ; Petersen JW; Brown GH; Anderson RD; Shuster JJ; Cook-Wiens G; Rogatko A; Pepine CJ
Eur Heart J; 2016 May; 37(19):1504-13. PubMed ID: 26614823
[TBL] [Abstract][Full Text] [Related]
10. Microvascular ischemia in patients with successful percutaneous coronary intervention: effects of ranolazine and isosorbide-5-mononitrate.
Golino M; Spera FR; Manfredonia L; De Vita A; Di Franco A; Lamendola P; Villano A; Melita V; Mencarelli E; Lanza GA; Crea F
Eur Rev Med Pharmacol Sci; 2018 Oct; 22(19):6545-6550. PubMed ID: 30338825
[TBL] [Abstract][Full Text] [Related]
11. Temporal Trends in Angina, Myocardial Perfusion, and Left Ventricular Remodeling in Women With No Obstructive Coronary Artery Disease Over 1-Year Follow-Up: Results From WISE-CVD.
Quesada O; Hermel M; Suppogu N; Aldiwani H; Shufelt C; Mehta PK; Cook-Wiens G; Maughan J; Berman DS; Thomson LEJ; Handberg EM; Pepine CJ; Bairey Merz CN; Wei J
J Am Heart Assoc; 2020 Jul; 9(13):e016305. PubMed ID: 32578481
[TBL] [Abstract][Full Text] [Related]
12. Ranolazine and Microvascular Angina by PET in the Emergency Department: Results From a Pilot Randomized Controlled Trial.
Safdar B; D'Onofrio G; Dziura J; Russell RR; Johnson C; Sinusas AJ
Clin Ther; 2017 Jan; 39(1):55-63. PubMed ID: 28081848
[TBL] [Abstract][Full Text] [Related]
13. Effect of Ranolazine on Ischemic Myocardium IN Patients With Acute Cardiac Ischemia (RIMINI-Trial): A Randomized Controlled Pilot Trial.
Schwemer TF; Radziwolek L; Deutscher N; Diermann N; Sehner S; Blankenberg S; Friedrich FW
J Cardiovasc Pharmacol Ther; 2019 Jan; 24(1):62-69. PubMed ID: 29938533
[TBL] [Abstract][Full Text] [Related]
14. Effects of the Antianginal Drugs Ranolazine, Nicorandil, and Ivabradine on Coronary Microvascular Function in Patients With Nonobstructive Coronary Artery Disease: A Meta-analysis of Randomized Controlled Trials.
Zhu H; Xu X; Fang X; Zheng J; Zhao Q; Chen T; Huang J
Clin Ther; 2019 Oct; 41(10):2137-2152.e12. PubMed ID: 31548105
[TBL] [Abstract][Full Text] [Related]
15. Ranolazine and the myocardial demand-supply balance.
Klocke FJ
JACC Cardiovasc Imaging; 2009 Nov; 2(11):1310-2. PubMed ID: 19909935
[No Abstract] [Full Text] [Related]
16. Coronary microvascular function is independently associated with left ventricular filling pressure in patients with type 2 diabetes mellitus.
Kawata T; Daimon M; Miyazaki S; Ichikawa R; Maruyama M; Chiang SJ; Ito C; Sato F; Watada H; Daida H
Cardiovasc Diabetol; 2015 Aug; 14():98. PubMed ID: 26242308
[TBL] [Abstract][Full Text] [Related]
17. Incremental Value of Transthoracic Doppler Echocardiography-Assessed Coronary Flow Reserve in Patients With Suspected Myocardial Ischemia Undergoing Myocardial Perfusion Scintigraphy.
Gan LM; Svedlund S; Wittfeldt A; Eklund C; Gao S; Matejka G; Jeppsson A; Albertsson P; Omerovic E; Lerman A
J Am Heart Assoc; 2017 Apr; 6(4):. PubMed ID: 28420647
[TBL] [Abstract][Full Text] [Related]
18. Preconditioning effects of adenosine in patients with severe coronary artery disease but preserved coronary flow reserve.
Sadigh B; Shahgaldi K; Sylvén C; Quintana M; Winter R
Coron Artery Dis; 2009 Aug; 20(5):354-9. PubMed ID: 19593890
[TBL] [Abstract][Full Text] [Related]
19. ChaMP-CMD: A Phenotype-Blinded, Randomized Controlled, Cross-Over Trial.
Sinha A; Rahman H; Douiri A; Demir OM; De Silva K; Clapp B; Webb I; Gulati A; Pinho P; Dutta U; Ellis H; Shah AM; Chiribiri A; Marber M; Webb AJ; Perera D
Circulation; 2024 Jan; 149(1):36-47. PubMed ID: 37905403
[TBL] [Abstract][Full Text] [Related]
20. Impact of myocardial diastolic dysfunction on coronary flow reserve in hypertensive patients with left ventricular hypertrophy.
Galderisi M; Cicala S; De Simone L; Caso P; Petrocelli A; Pietropaolo L; Celentano A; Mininni N; de Divitiis O
Ital Heart J; 2001 Sep; 2(9):677-84. PubMed ID: 11666096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
